136 related articles for article (PubMed ID: 17224708)
1. Weight gain during a double-blind multidosage clozapine study.
de Leon J; Diaz FJ; Josiassen RC; Cooper TB; Simpson GM
J Clin Psychopharmacol; 2007 Feb; 27(1):22-7. PubMed ID: 17224708
[TBL] [Abstract][Full Text] [Related]
2. Plasma clozapine concentration coefficients of variation in a long-term study.
Diaz FJ; de Leon J; Josiassen RC; Cooper TB; Simpson GM
Schizophr Res; 2005 Jan; 72(2-3):131-5. PubMed ID: 15560958
[TBL] [Abstract][Full Text] [Related]
3. Predicting Weight Gain in Patients Treated With Clozapine: The Role of Sex, Body Mass Index, and Smoking.
Lau SL; Muir C; Assur Y; Beach R; Tran B; Bartrop R; McLean M; Caetano D
J Clin Psychopharmacol; 2016 Apr; 36(2):120-4. PubMed ID: 26872115
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial.
Diaz FJ; Josiassen RC; de Leon J
J Clin Psychopharmacol; 2018 Oct; 38(5):442-446. PubMed ID: 30106876
[TBL] [Abstract][Full Text] [Related]
5. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.
Couchman L; Morgan PE; Spencer EP; Flanagan RJ
Ther Drug Monit; 2010 Aug; 32(4):438-47. PubMed ID: 20463634
[TBL] [Abstract][Full Text] [Related]
6. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
[TBL] [Abstract][Full Text] [Related]
7. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.
Rostami-Hodjegan A; Amin AM; Spencer EP; Lennard MS; Tucker GT; Flanagan RJ
J Clin Psychopharmacol; 2004 Feb; 24(1):70-8. PubMed ID: 14709950
[TBL] [Abstract][Full Text] [Related]
8. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
9. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.
Kumra S; Kranzler H; Gerbino-Rosen G; Kester HM; De Thomas C; Kafantaris V; Correll CU; Kane JM
Biol Psychiatry; 2008 Mar; 63(5):524-9. PubMed ID: 17651705
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of high-dose olanzapine in a double-blind crossover study.
Kelly DL; Richardson CM; Yu Y; Conley RR
Hum Psychopharmacol; 2006 Aug; 21(6):393-8. PubMed ID: 16850522
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.
Lu ML; Lane HY; Lin SK; Chen KP; Chang WH
J Clin Psychiatry; 2004 Jun; 65(6):766-71. PubMed ID: 15291653
[TBL] [Abstract][Full Text] [Related]
12. The significance of sampling time in therapeutic drug monitoring of clozapine.
Jakobsen MI; Larsen JR; Svensson CK; Johansen SS; Linnet K; Nielsen J; Fink-Jensen A
Acta Psychiatr Scand; 2017 Feb; 135(2):159-169. PubMed ID: 27922183
[TBL] [Abstract][Full Text] [Related]
13. Double-blind study of clozapine dose response in chronic schizophrenia.
Simpson GM; Josiassen RC; Stanilla JK; de Leon J; Nair C; Abraham G; Odom-White A; Turner RM
Am J Psychiatry; 1999 Nov; 156(11):1744-50. PubMed ID: 10553738
[TBL] [Abstract][Full Text] [Related]
14. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
Cooper GD; Harrold JA; Halford JC; Goudie AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
[TBL] [Abstract][Full Text] [Related]
15. Clozapine: Dose, Sex, Ethnicity, Smoking Habit, Age, Body Weight, and Plasma Clozapine and N -Desmethylclozapine (Norclozapine) Concentrations in Clinical Practice.
Flanagan RJ; Hunter S; Obee SJ; Reeves S
J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):131-138. PubMed ID: 36735578
[TBL] [Abstract][Full Text] [Related]
16. Clozapine: more than 900 mg/day may be needed.
Maccall C; Billcliff N; Igbrude W; Natynczuk S; Spencer EP; Flanagan RJ
J Psychopharmacol; 2009 Mar; 23(2):206-10. PubMed ID: 18515467
[TBL] [Abstract][Full Text] [Related]
17. Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex).
Couchman L; Morgan PE; Spencer EP; Johnston A; Flanagan RJ
Ther Drug Monit; 2010 Oct; 32(5):624-7. PubMed ID: 20720516
[TBL] [Abstract][Full Text] [Related]
18. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.
Kluge M; Schuld A; Himmerich H; Dalal M; Schacht A; Wehmeier PM; Hinze-Selch D; Kraus T; Dittmann RW; Pollmächer T
J Clin Psychopharmacol; 2007 Dec; 27(6):662-6. PubMed ID: 18004133
[TBL] [Abstract][Full Text] [Related]
19. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics.
Lane HY; Chang YC; Chang WH; Lin SK; Tseng YT; Jann MW
J Clin Psychiatry; 1999 Jan; 60(1):36-40. PubMed ID: 10074876
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions.
Tan MSA; Honarparvar F; Falconer JR; Parekh HS; Pandey P; Siskind DJ
Psychopharmacology (Berl); 2021 Mar; 238(3):615-637. PubMed ID: 33410989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
